MODIFIED LABELING OF CARDIAC ASSIST INTRA-AORTIC BALLOON CATHETERS: MODEL 930 - 940, 30 - 40 CC SENSATION AND NICATH 30C
Device Facts
| Record ID | K963187 |
|---|---|
| Device Name | MODIFIED LABELING OF CARDIAC ASSIST INTRA-AORTIC BALLOON CATHETERS: MODEL 930 - 940, 30 - 40 CC SENSATION AND NICATH 30C |
| Applicant | Boston Scientific Corp |
| Product Code | DSP · Cardiovascular |
| Decision Date | Nov 4, 1996 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 870.3535 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
Refractory power failure. Cardiogenic shock. Unstable refractory angina. Impending or extending myocardial infarction (MI). Hemodynamically significant mechanical complications secondary to acute MI: Ventricular septal defect. Mitral valve regurgitation. Papillary muscle rupture. Angiography/angioplasty patients. Septal shock.
Device Story
Intra-Aortic Balloon Catheters (IABs) consist of polyurethane blend balloon on polyurethane-covered nylon shaft; coated with medical grade silicone fluid. Central lumen allows over-the-wire placement. Device inserted into aorta to provide circulatory support. Used in clinical settings for patients with cardiac complications; operated by physicians. Proposed modification allows optional sheathless insertion technique. Bench testing confirms device tracks guidewire, resists kinking, and maintains structural integrity during insertion through restricted openings. Output is mechanical circulatory assistance. Benefits include hemodynamic stabilization in acute cardiac failure.
Clinical Evidence
No clinical data. Bench testing only, including insertion tests through adjustable restrictions, kink resistance testing, trackability assessment, and dimensional comparisons against predicate devices.
Technological Characteristics
Polyurethane blend balloon; polyurethane-covered nylon shaft; medical grade silicone fluid coating. Central lumen for guidewire. Sterilized via ethylene oxide gas. Packaged in plastic trays with Tyvek/Mylar pouches.
Indications for Use
Indicated for patients experiencing refractory power failure, cardiogenic shock, unstable refractory angina, impending or extending myocardial infarction, or hemodynamically significant mechanical complications secondary to acute MI (ventricular septal defect, mitral valve regurgitation, papillary muscle rupture), as well as patients undergoing angiography/angioplasty or experiencing septal shock.
Regulatory Classification
Identification
An intra-aortic balloon and control system is a prescription device that consists of an inflatable balloon, which is placed in the aorta to improve cardiovascular functioning during certain life-threatening emergencies, and a control system for regulating the inflation and deflation of the balloon. The control system, which monitors and is synchronized with the electrocardiogram, provides a means for setting the inflation and deflation of the balloon with the cardiac cycle.
Special Controls
*Classification.* (1) Class II (special controls) when the device is indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure. The special controls for this device are:(i) Appropriate analysis and non-clinical testing must be conducted to validate electromagnetic compatibility and electrical safety of the device; (ii) Software verification, validation, and hazard analysis must be performed; (iii) The device must be demonstrated to be biocompatible; (iv) Sterility and shelf-life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components; (v) Non-clinical performance evaluation of the device must demonstrate mechanical integrity, durability, and reliability to support its intended purpose; and (vi) Labeling must include a detailed summary of the device- and procedure-related complications pertinent to use of the device. (2) Class III (premarket approval) when the device is indicated for septic shock and pulsatile flow generation. (c) *Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 31, 2014, for any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976, or that has, on or before March 31, 2014, been found to be substantially equivalent to any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976. Any other intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
Reference Devices
- Arrow 9 F 40 cc IAB